title: Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer.
authors.affiliation: Department of Oncology, S. Raffaele Scientific, Institute, Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Cereda
authors.forename: A
authors.initials: A
authors.lastname: Rognone
authors.forename: E
authors.initials: E
authors.lastname: Mazza
authors.forename: C
authors.initials: C
authors.lastname: Fugazza
authors.forename: D
authors.initials: D
authors.lastname: Ceraulo
authors.forename: E
authors.initials: E
authors.lastname: Villa
authors.forename: M
authors.initials: M
authors.lastname: Reni
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016879:Salvage Therapy / Q000379:methods*; D000093542:Gemcitabine
chemical_list: D000903:Antibiotics, Antineoplastic; D003841:Deoxycytidine; D015251:Epirubicin; D000093542:Gemcitabine